Clinical Trial Results:
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation
and Expansion Study of Gilteritinib (ASP2215) Combined with
Chemotherapy in Children, Adolescents and Young Adults with FMS-like
Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD)
Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Summary
|
|
EudraCT number |
2018-002301-61 |
Trial protocol |
GB DE ES IT |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 May 2026
|
First version publication date |
02 May 2026
|
Other versions |
|
Summary report(s) |
EU CTIS Results Redirect |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.